According to the latest industry analysis by Future Market Insights, the global obesity-diabetes drugs market valued at approximately USD 56,739.0 million in 2024. The market is projected to exhibit moderate growth with a compound annual growth rate (CAGR) of 5.6% over the forecast period, reaching an estimated valuation of USD 97,567.4 million by 2034.
Therapeutic drugs play a crucial role in the effective management of obesity-diabetes, assisting patients in controlling blood sugar levels and preventing further complications. The increasing prevalence of obesity-diabetes is largely attributed to the growing number of individuals leading sedentary lifestyles with limited physical activity. This trend significantly contributes to the expansion of the market segment.
Get Sample Report Visit: https://www.futuremarketinsights.com/reports/sample/rep-gb-19677
Additionally, the genetic complexities inherited by diverse populations in emerging countries are expected to further drive market growth. As these populations face unique health challenges, the demand for effective obesity-diabetes drugs continues to rise, supporting the overall market trajectory.
Key Takeaways from the Market Study:
- By therapy, the drug therapy to hold the dominant share of 9% in 2024 in the market. The growth of the segment is majorly due to its easy availability and affordability among common population.
- By route of administration, oral route of administration segment to account for a major share of 6% in the market in 2024. This is due to its convenience in consumption. In addition, its safety and efficacy profile furthers augments its market growth.
- By distribution channels, institutional segment which includes hospitals will dominate the market by holding the market share of 7% in 2024. The increasing footfall of patients to the hospitals for their regular check-up anticipates the growth of the segment.
- North America region is considered the leading region with a value share of 5% in 2024. The rising prevalence of obese population in the region surges the growth of the market in the region.
“Novel pharmacological discoveries targeting particular pathways in metabolic diseases, along with personalized medicine methods, are specifically driving growth in the obesity diabetes drug industry,” says an analyst of Future Market Insights.
Customization Available Upon Request: https://www.futuremarketinsights.com/customization-available/rep-gb-19677
Market Competition:
The primary approach taken by the key operating players in the industry is to develop novel therapeutic options for the management of obesity-diabetes. The major aim of the key players is to expand their product portfolio through the introduction of new products and uphold their position in the market. Following are a few examples of research and development activities made by them to be at the top position:
- In November 2023, Eli Lilly and Company received approval for Zepbound from the U.S. FDA. This Zepbound injection is indicated for the treatment of adults with obesity and have weight related metabolic problems including type 2 diabetes mellitus.
- In November 2023, Astrazeneca collaborated with Eccogene, a Chinese biopharmaceutical company for research and development of ECC5004, which is an investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) indicated for the treatment of obesity, and type 2 diabetes.
Leading Obesity-Diabetes Drugs Brands:
- Boehringer Ingelheim International GmbH.
- Eli Lilly and Company
- Sanofi
- Vertex Pharmaceuticals Incorporated
- Novo Nordisk A/S
- AstraZeneca
- MannKind Corporation
- Xeris Pharmaceuticals
- Amphastar Pharmaceuticals, Inc.
- Novartis
- Bayer AG
- GLENMARK PHARMACEUTICALS LTD.
- Others
A Detailed Full Report: https://www.futuremarketinsights.com/checkout/19677
Key Segments of Market Report:
By Therapy:
As per product type, the industry has been categorized into drug therapy (Meglitinides, sulfonylureas, Dipeptidyl-peptidase 4 (DPP-4) inhibitors, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, sodium-glucose co-transporter 2 (SGLT2) inhibitors, bile acid sequestrants and GLP-1 receptor agonists), and insulin therapy (rapid acting insulin, short acting insulin, intermediate acting insulin, long acting insulin and biphasic insulin.
By Route of Administration:
This segment is further categorized into oral administration, nasal administration and parenteral administration (subcutaneous, intramuscular and intravenous).
By Distribution Channel:
Different sales channels include Institutional sales (hospitals, specialty clinics, and others), retail sales (retail pharmacies, and drug stores) and online pharmacy.
By Region:
Industry analysis has been carried out in key countries of North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
